Compounding Pharmacies’ Potential Future Role in the Administration of Psychedelic Drugs Like Psilocybin

Peter Koshland, PharmD, CEO of Koshland Pharm and a practicing pharmacist, discusses whether the process may be similar in the future in terms of compounding pharmacies’ role in the administration of psychedelic drugs like psilocybin.

Pharmacy Times interviewed Peter Koshland, PharmD, CEO of Koshland Pharm and a practicing pharmacist, on the current role of the pharmacist in ketamine therapy. Koshland’s compounding pharmacy is based in San Francisco and has worked in the ketamine therapy space since the FDA approval of the drug.

During the discussion, Koshland addresses whether there are any regulatory compliance steps that compounding pharmacies take when putting together ketamine dosages and dosages for other drugs in the psychedelic medicine space that have been FDA-approved, whether the process may be similar in the future in terms of compounding pharmacies’ role in the administration of other psychedelic drugs like psilocybin upon FDA approval, and whether there are any advances in psychedelic research that may impact the work of compounding pharmacies in the years to come.